Behrad Derakhshan - 12 Aug 2026 Form 4/A - Amendment Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Chief Business Officer
Issuer ticker: EWTX
Reported as of: 12 Aug 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 17 Aug 2026, 18:39:47 UTC
Original report date: 14 Aug 2026
Prior SEC filing: 14 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ John R Moore Attorney-in-Fact for Behrad Derakhshan

Key filing fact

Behrad Derakhshan filed Form 4/A - Amendment for Edgewise Therapeutics, Inc. (EWTX) on 17 Aug 2026.

Key facts

This page summarizes Behrad Derakhshan's Form 4/A - Amendment filing for Edgewise Therapeutics, Inc. (EWTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2026, 18:39.

Change

Previous filing in this sequence was filed on 14 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001853109 Primary reporting owner

Derakhshan Behrad

Relationship: Chief Business Officer
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: /s/ John R Moore Attorney-in-Fact for Behrad Derakhshan
Signature date: 17 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $43.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC remarks

This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.